A study on treatment outcome and adverse drug reactions among extra pulmonary tuberculosis patients treated under DOTS in a tertiary care hospital


  • Priyadarshini Bai G. Department of Pharmacology, Sri Siddhartha Medical College, Tumakuru, Karnataka, India
  • Ravikumar P. Department of Pulmonary Medicine, Sri Siddhartha Medical College, Tumakuru, Karnataka, India




ATT - antitubercular drugs, ADR - Adverse drug reactuins, DOTS -Directly Observed Treatment Short-course, Extra-pulmonary Tuberculosis, Hartwig’s scale, Naronjo’s causality assessment scale, World Health Organization -Uppsala monitoring centre (WHO-UMC)


Background: Pulmonary tuberculosis being the predominant manifestation of the disease Extra-Pulmonary sites can also involve as a result of dissemination from a chief focus. The present study aims to determine the presentation and outcome of patients with extra-pulmonary tuberculosis treated with category I DOTS and to identify the incidence and pattern of ADRs caused by anti-tubercular drugs and to assess the causality and severity of the reported ADRs.

Methods: Data was collected from cases of Tuberculosis patients diagnosed and treated under category I DOTS at Sri Siddhartha Medical College for the period of one year (during 2015). These patients were monitored for ADRs during OPDs and hospital stay. Any Adverse effects observed were recorded in ‘Adverse Drug Event Reporting Form’ prepared by the CDSCO, Govt. of India. The data were evaluated for patient demography, types of TB, incidence of ADRs, onset and outcome of the ADRs. ADRs were also assessed for their causality and severity by using WHO-UMC criteria and Hartwig’s scale.

Results: Extra-pulmonary cases accounted for 32.2% of total TB cases. Among 224 cases of extra-pulmonary TB studied, 136 (60.7%) were males and 88 (39.3%) were females. Among these patients 82.2% completed treatment, 7.5% were defaulted, 9.9% died and 0.4% treatment failure. The most common reason for default was irregular treatment (29.5%) followed by alcohol abuse (23.5%). Among 224 patients of EPTB who were started on ATT as per DOTS, we noted ADR in 52 patients and 73 ADRs. Gastritis was the most common ADR (25%) followed by anorexia (14%) and skin reactions (9.6%) and multiple drug therapy was the major predisposing factor for these ADR’s.

Conclusions: Extra-pulmonary Tuberculosis accounts for 32.2% of the total cases studied. Treatment irregularities and alcohol abuse are the two most common reasons for default. On evaluation of the causality of ADRs, majority of them were found to be ‘possible’ by WHO-UMC and Naronjo’s causality assessment scale. The severity assessment of ADRs showed that 42% reactions were moderate and 58% were of the ‘mild’ nature.


Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician. 2005;72(9):1761-8.

Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis. 2005;5(7):415-30. http://dx.doi.org/10.1016/S1473-3099(05)70163-8.

Global tuberculosis report. 2015. Available: http://apps.who.int/iris/bitstream/10665/191102/1/ 9789241565059_eng.pdf

Gupta KB, Kumar A, Sen R, Sen J, Verma M. Role of ultrasonography and computed tomography in complicated cases of tuberculous cervical lymphadenitis. Indian J Tuberc. 2007;54:71-8.

Nader LA, Mattos AA, Picon PD, Bassanesi SL, Mattos AZ, Rodriguez MP. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: Is anti-HCV a risk factor? Annals of Hepatol. 2010;9:70-4.

Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH. Design of the anti-tuberculosis drugs induced adverse reactions in China national Tuberculosis prevention and cotroscheme study. BMC Public Health. 2010;10:267-76.

Schaberg TK, Rebhan, Lode H. Risk factors for side effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026-30.

Okanurak K, Kitayapor D, Wanarangsikul W, Koompong C. Effectiveness of DOT for tuberculosis treatment outcome: a prospective study in Bangkok, Thailand Int J Tuberc Lung QQ disease. 2007;11(7):762-8.

Diel R, Niemann S. Outcome of tuberculosis treatment in Hamburg: a survey 1997-2001. Int J Tuberc Lung Dis. 2003;7(2):124-31.

Khan MA, Basit A, Ziaullah .Javaid A. Outcome of tuberculosis patients registered during 2007 in major teaching hospitals of Peshawar. JPMI 2009;23(04):358-62.

Chennaveerappa PK, Siddharam SM, Halesha BR, Vittal BG, Jayashree N. Treatment outcome of tuberculosis patients registered at dots centre in a teaching hospital, south India. Int J Biol Med Res. 2011;2(2):487-9.

Chandrashekaran V, Gopi PG, Subramani R, Thomas A, Jaggarajamma K, Narayanan PR. Default during the intensive phase of treatment under DOTS programme. Indian J Tuberc. 2005;52:197-02.

Tekle B, Mariam DH, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia lnt J Tuberc Lung Dis. 2002;6(7):573-9.

Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first- Line anti tuberculosis drugs among patients treated for active tuberculosis, Am J Respir Crit Care Med. 2003;167:1472-7.

Tak DK. Safety Evaluation of Antitubercular Therapy Under Revised National Tuberculosis Control Programme In India, JCDR. 2009;3:1395-401.

Daphne Y, Marthe P. Incidence of serious side effects from First-line antituberculosis drugs among patients treated for Active Tuberculosis, Am J Resp Crit Care Med. 2003;167:1472-7.

Dhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K, Jain SK. Adverse drug reactions observed during DOTS, J Commun Dis. 2004;36:251-9.




How to Cite

G., P. B., & P., R. (2016). A study on treatment outcome and adverse drug reactions among extra pulmonary tuberculosis patients treated under DOTS in a tertiary care hospital. International Journal of Basic & Clinical Pharmacology, 6(1), 48–52. https://doi.org/10.18203/2319-2003.ijbcp20164496



Original Research Articles